<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678860</url>
  </required_header>
  <id_info>
    <org_study_id>080135</org_study_id>
    <secondary_id>08-EI-0135</secondary_id>
    <nct_id>NCT00678860</nct_id>
  </id_info>
  <brief_title>Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires</brief_title>
  <official_title>Pilot Validation Study of Computer Administration of Vision Targeted Quality of Life Instruments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will test and compare computerized and paper versions of eye questionnaires.&#xD;
      Questionnaires are used in medicine to gain a better understanding of how a disease can&#xD;
      impact a person's quality of life. Computerized versions of such questionnaires are often as&#xD;
      good as or better than paper versions, but there has been no direct comparison of the two.&#xD;
      This study may help in the development of eye questionnaires used to understand symptoms and&#xD;
      monitor patients in clinical trials.&#xD;
&#xD;
      People 21 years of age and older with ocular surface disease (OSD) and matched control&#xD;
      subjects without OSD may be eligible for this study. All participants undergo the following&#xD;
      procedures:&#xD;
&#xD;
        -  Medical and eye history.&#xD;
&#xD;
        -  Vision test and examination of the front part of the eye.&#xD;
&#xD;
        -  Tear measurement: A small piece of paper is placed on the surface of the eye to measure&#xD;
           the amount of tears produced. The consistency of the tears is measured by looking at how&#xD;
           fast they evaporate from the surface of the eye.&#xD;
&#xD;
        -  Completion of either paper-based or computer-based version of a questionnaire 15 minutes&#xD;
           after the eye examination and completion of the other version within 1 week at home.&#xD;
           (Subjects who complete the paper version in the clinic are told how to access the&#xD;
           computer version online at home or on a library computer; those who complete the&#xD;
           computer version in the clinic are given a paper version to take home.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this protocol is to compare the health-related quality of life (visual&#xD;
      function) reported by participants when using web-based questionnaires versus their responses&#xD;
      obtained when using standard paper versions of the questionnaires. This comparison will be&#xD;
      performed in a population of patients diagnosed with ocular surface disease (OSD) and in age-&#xD;
      and gender-matched controls by using a randomized, cross-over study design. This type of&#xD;
      comparative study of patient-reported outcomes has been reported for rheumatology,&#xD;
      cardiology, psychiatry, asthma, alcoholism, pain assessment, gastrointestinal disease,&#xD;
      diabetes, and allergy populations; however, to our knowledge there have been no reports of&#xD;
      such a study from patients with ocular disease. The study will evaluate the agreement between&#xD;
      scores reported via two modes of administration: a web-based version and a paper-and-pencil&#xD;
      version. Components of three questionnaires commonly used to evaluate visual function,&#xD;
      symptoms, and vision-related quality of life in OSD will be included: the initial 5 questions&#xD;
      of the Ocular Surface Index (OSDI), question #15 of the National Eye Institute Visual&#xD;
      Functioning Questionnaire - 25 (VFQ-25), and specified domains of the National Eye Institute&#xD;
      Refractive Error Quality Of Life Instrument-42 (RQL-42) (clarity of vision, near vision, far&#xD;
      vision, glare, symptoms, worry, and satisfaction with correction).&#xD;
&#xD;
      The study will also evaluate whether there are differences in mean overall score by age,&#xD;
      gender, order of administration, or disease severity.&#xD;
&#xD;
      Ocular surface disease, which includes dry eye disease secondary to a variety of etiologies,&#xD;
      is an ophthalmic condition which places a burden not just on functional vision, but also on&#xD;
      overall health related quality of life (HRQoL), with an impact similar to that of moderate&#xD;
      angina3. This study will add to the body of knowledge in the field of patient-reported&#xD;
      outcome measures (PROs), and will be the first to compare the computerized, web-based and&#xD;
      paper-based versions of previously validated questionnaires used to assess QoL in subjects&#xD;
      with ocular disease.&#xD;
&#xD;
      There has been an increasing interest in assessing PROs in many fields of medicine,&#xD;
      especially in the context of clinical trials where HRQoL is an important component of the&#xD;
      overall evaluation of an intervention or treatment. As the use of computers increases and&#xD;
      accessibility to the internet broadens, there is a tremendous potential in harnessing this&#xD;
      technology in the future as a cost-effective, efficient way to gather clinical data on PROs&#xD;
      for future ophthalmic clinical trials and studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 9, 2008</start_date>
  <completion_date>October 31, 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">147</enrollment>
  <condition>Eye Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        The study cohort will be comprised of eighty (80) participants diagnosed with OSD and 40&#xD;
        controls without OSD comprised of similar numbers of men and women.&#xD;
&#xD;
        INCLUSION CRITERIA FOR OSD GROUP:&#xD;
&#xD;
          -  Patients greater than or equal to 18 years of age with a diagnosis of ocular surface&#xD;
             disease confirmed by investigator.&#xD;
&#xD;
          -  Schirmer I less than 10 mm wetting over 5 minutes OR tear breakup time less than or&#xD;
             equal to 5 seconds.&#xD;
&#xD;
          -  Binocular visual acuity at near equal to or greater than 20/40 (Jaeger 3) with&#xD;
             habitual correction.&#xD;
&#xD;
          -  Literacy and fluency in English sufficient to follow study instructions and likely to&#xD;
             be able to comprehend the questionnaires.&#xD;
&#xD;
          -  Ability and willingness to complete the study protocol.&#xD;
&#xD;
        EXCLUSION CRITERIA FOR OSD GROUP:&#xD;
&#xD;
          -  Ocular surgery or infection within 3 months of study enrollment.&#xD;
&#xD;
          -  Inability to obtain appropriate consent.&#xD;
&#xD;
          -  Allergy or sensitivity to any medication used in study.&#xD;
&#xD;
          -  Subject has a situation or condition, which in the investigator's opinion, may put the&#xD;
             subject at a significant risk, may confound the study result, or may interfere&#xD;
             significantly with the participation in the study.&#xD;
&#xD;
          -  Uncontrolled systemic disease.&#xD;
&#xD;
          -  Active ocular disease other than ocular surface disease which in the investigator's&#xD;
             opinion may put the subject at a significant risk, may confound the study result, or&#xD;
             may interfere significantly with the participation in the study.&#xD;
&#xD;
          -  Any disability preventing timely, efficient completion of writing or keyboarding&#xD;
             tasks.&#xD;
&#xD;
          -  Incapable of providing informed consent.&#xD;
&#xD;
          -  Monocular vision (legal blindness in one eye).&#xD;
&#xD;
        INCLUSION CRITERIA FOR CONTROL GROUP:&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Schirmer I test greater than or equal to 10 mm wetting over 5 minutes OR tear breakup&#xD;
             time greater than 5 seconds.&#xD;
&#xD;
          -  Binocular visual acuity at near equal to or greater than 20/40 (Jaeger 3) with&#xD;
             habitual correction&#xD;
&#xD;
          -  Literacy and fluency in English sufficient to follow study instructions and likely to&#xD;
             be able to comprehend the questionnaire&#xD;
&#xD;
          -  Ability and willingness to complete the study protocol&#xD;
&#xD;
        EXCLUSION CRITERIA FOR CONTROL GROUP:&#xD;
&#xD;
          -  A diagnosis of ocular surface disease made by a clinician&#xD;
&#xD;
          -  Ocular surgery or infection within 6 months of study enrollment&#xD;
&#xD;
          -  Pupillary, motility, convergence or accommodative ocular disorder judged by&#xD;
             investigator to have potential to negatively impact ease of near and intermediate&#xD;
             binocular visual function&#xD;
&#xD;
          -  Inability to obtain appropriate consent&#xD;
&#xD;
          -  Allergy or sensitivity to any medication used in study.&#xD;
&#xD;
          -  Monocular vision (legal blindness in one eye) or subject has a situation or condition,&#xD;
             which in the investigator's opinion, may put the subject at a significant risk, may&#xD;
             confound the study results, or may interfere significantly with the participation in&#xD;
             the study.&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
&#xD;
          -  Active ocular disease which in the investigator's opinion may put the subject at a&#xD;
             significant risk, may confound the study result, or may interfere significantly with&#xD;
             the participation in the study&#xD;
&#xD;
          -  Any disability preventing timely, efficient completion of writing or keyboarding tasks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993 Apr;2(2):153-9.</citation>
    <PMID>8518769</PMID>
  </reference>
  <reference>
    <citation>MiljanoviÄ‡ B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007 Mar;143(3):409-15. Epub 2007 Jan 2.</citation>
    <PMID>17317388</PMID>
  </reference>
  <reference>
    <citation>Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003 Jul;110(7):1412-9.</citation>
    <PMID>12867401</PMID>
  </reference>
  <verification_date>October 31, 2011</verification_date>
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Questionnaire</keyword>
  <keyword>Computer Assisted Interface</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Dry Eye</keyword>
  <keyword>Ocular Surface Disease</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

